vTv Therapeutics Inc. Class A Common Stock (VTVT) Stock Price

VTVTStock

$33.91−69.59%52W

Market Cap$134.08M

P/E—

PEG Ratio—

Div yield—

Beta0.20

VTVT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-20.22%

Price vs S&P 500 (4W)5.99%

VGM Score52.47

Book Value / Share (Quarterly)$22.84

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-36.70%

Cash Flow / Share (Quarterly)$-2.64

Price vs S&P 500 (YTD)-27.21%

Net Profit Margin (TTM)65.51%

EPS (TTM)$-0.92

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-0.92

Revenue Growth (5Y)-18.10%

EPS (Annual)$-3.20

ROI (Annual)-41.86%

Net Profit Margin (5Y Avg)-738.57%

Cash / Share (Quarterly)$24.90

P/E Basic Excl Extra (TTM)55.59x

ROA (Last FY)-30.00%

Revenue Growth TTM (YoY)216600.00%

EBITD / Share (TTM)$-0.29

Operating Margin (TTM)63.15%

Cash Flow / Share (Annual)$-6.41

P/B Ratio1.39x

P/B Ratio (Quarterly)1.74x

Net Income / Employee (Annual)$-1,037,500

EV / Revenue (TTM)0.74x

Net Interest Coverage (TTM)-1761.00x

ROA (TTM)2.86%

EPS Incl Extra (Annual)$-3.20

Current Ratio (Annual)13.54x

Quick Ratio (Quarterly)14.28x

3-Month Avg Trading Volume0.07M

52-Week Price Return-69.59%

P/E Incl Extra (TTM)55.59x

Revenue / Employee (TTM)$1,416,900

Tangible BV / Share (Quarterly)$-1.00

P/S Ratio (Annual)123.09x

Asset Turnover (Annual)0.03x

52-Week High$44.00

Operating Margin (5Y Avg)-995.06%

EPS Excl Extra (Annual)$-3.20

26-Week Price Return-8.97%

Quick Ratio (Annual)13.42x

13-Week Price Return-4.54%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)14.36x

Enterprise Value$27.09M

Revenue / Share Growth (5Y)14.10%

Asset Turnover (TTM)0.37x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-2222.71%

Cash / Share (Annual)$22.58

3-Month Return Std Dev49.40%

Net Income / Employee (TTM)$86,600

ROE (Last FY)-41.86%

Net Interest Coverage (Annual)-541.50x

EPS Basic Excl Extra (Annual)$-3.20

Receivables Turnover (TTM)12.40x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.92

Receivables Turnover (Annual)12.40x

ROI (TTM)3.95%

P/S Ratio (TTM)3.40x

Pretax Margin (5Y Avg)-976.86%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$-0.43

Price vs S&P 500 (52W)-73.14%

P/E Ratio (TTM)55.59x

Year-to-Date Return-15.25%

5-Day Price Return7.66%

EPS Normalized (Annual)$-3.20

ROA (5Y Avg)-74.14%

Net Profit Margin (Annual)-1815.34%

Month-to-Date Return4.76%

Cash Flow / Share (TTM)$-13.50

EBITD / Share (Annual)$-3.89

Operating Margin (Annual)-2377.58%

P/E Excl Extra (TTM)55.59x

EPS Basic Excl Extra (TTM)$-0.92

P/B Ratio (Annual)2.59x

Pretax Margin (TTM)65.51%

Book Value / Share (Annual)$16.36

Price vs S&P 500 (13W)-7.33%

Beta0.20x

Revenue / Share (TTM)$2.52

ROE (TTM)3.96%

52-Week Low$14.55

vGradeB

gGradeC

mGradeD

vgmGradeC

VTVT Earnings Surprise History

Q2 25-0.92est. -0.82

Q3 25-1.08est. -0.98

Q4 25-0.58est. -1.09

Q1 261.65est. 0.21

Q2 26-1.05est. -1.08

VTVT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.18

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
VTVTvTv Therapeutics Inc. Class A Common Stock	B	C	D	$33.91
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About vTv Therapeutics Inc. Class A Common Stock

vTv Therapeutics is a late-stage biopharmaceutical company developing oral, small molecule drug candidates for diabetes and chronic diseases. The company's clinical pipeline is led by cadisegliatin, currently in Phase 3 trials, a potential first-in-class oral glucokinase activator for type 1 diabetes. vTv has a diverse pipeline of additional molecules in development across multiple disease indications.